Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)

Catalytic depolymerisation of suberin rich biomass with precious metal catalysts

“…PARPi single-agent therapy has been thoroughly investigated in phase 1/2 trials in women with ovarian cancer (see Table 1) [37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53]. These trials predominantly enrolled women with high-grade serous ovarian carcinoma and a germline BRCA1/2 mutation (gBRCA mt).…”

“…Across all phase 1/2 trials investigating PARPi as a single-agent therapy women with platinum-sensitive ovarian cancer achieved better ORRs compared to those with platinum-resistant/refractory disease (see Table 1). In addition, a number of trials demonstrated that a longer platinum-free interval (PFI) correlated with a higher likelihood of achieving an anti-tumour response [41,43,47,54].…”

Novel Systemic Treatments in High Grade Ovarian Cancer

“…Rucaparib was granted accelerated FDA approval largely based on composite data from 2 phase II studies. 106 patients with gBRCA mutations who had received at least 2 prior lines of chemotherapy received continuous rucaparib at 600 mg BD [61]. The confirmed ORR by RECIST was 54%.…”

Recommendations of the Polish Gynecological Oncology Society for the diagnosis and treatment of ovarian cancer

“…Leczenie należy prowadzić u wybranych chorych w dobrym stanie ogólnym, bez istotnych przetrwałych powikłań, z motywacją do leczenia. Nosiciele mutacji BRCA1/2 w przypadku braku odpowiedzi na leczenie po 2 lub więcej liniach chemioterapii mogą być poddani leczeniu za pomocą rucaparybu w monoterapii (41) lub po 3 lub więcej liniach olaparybem w monoterapii (42) (rejestracja w chwili obecnej jedynie w USA).…”

“…Treatment may be attempted in selected patients with a good performance status and no persistent adverse effects, well-motivated for treatment. Carriers of BRCA1/2 mutation with no response to treatment after 2 or more cycles may be switched to rucaparib monotherapy (41) , or after 3 or more cycles -olaparib monotherapy (42) (currently licensed only in the USA).…”